AMENDMENT NO. 2 TO LICENSE AND DEVELOPMENT AGREEMENT

THIS AMENDMENT NO. 2 TO LICENSE AND DEVELOPMENT AGREEMENT (this “ Amendment ”), dated as of May 15, 2006, is entered into by and between NovaDel Pharma, Inc. , a Delaware corporation (“ NovaDel ”), and Hana Biosciences, Inc. , a Delaware corporation (the “ Licensee ”). NovaDel and Licensee each may be referred to herein individually as a “ Party ,” or collectively as the “ Parties .”

WHEREAS, the Parties entered into that certain License and Development Agreement dated October 26, 2004, as amended on August 8, 2005 (the “ Agreement ”), pursuant to which Licensee licensed from NovaDel certain exclusive rights to develop and commercialize a pharmaceutical product containing ondansetron as an active ingredient that will be administered to humans using the Technology on the terms and conditions set forth in the Agreement;

WHEREAS , the Agreement provided that NovaDel would retain rights to certain “Information and Inventions” (as such terms are defined in the Agreement) conceived or developed following the date of the Agreement;

WHEREAS , the terms Information and Invention were not limited in scope to merely information and inventions relating to the Licensed Process, Licensed Product(s) or Licensed Technology, but to any information or inventions subsequently discovered by the parties, even if outside the scope of the Agreement; and

WHEREAS, the parties desire to amend the Agreement to clarify the parties’ intentions with regard to the meanings of the terms Information and Inventions.

NOW, THEREFORE,  in consideration of the foregoing premises, the mutual promises and covenants of the Parties contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound, do hereby agree as follows:

1.    Definition of Information and Inventions . Section 1.5 of the Agreement shall be amended and